Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2024Advanced Drug Delivery ReviewsOpen Access

Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics

View Full Paper
Ask AI
Bookmark
Share

Authors

PGPaula Gil-CabrerizoTSTeresa Simón‐YarzaEGElisa Garbayo

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gil-Cabrerizo et al. (2024) studied this question.

synapsesocial.com/papers/68e7079eb6db643587681f12https://doi.org/10.1016/j.addr.2024.115302
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease2022 · 22 citations
  2. 2Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System <i>In Vivo</i> to Treat Heart Disease2022 · 11 citations
  3. 3Optimizing Cardiac Delivery of Modified mRNA2017 · 114 citations
  4. 4MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload–Induced Heart Failure2017 · 173 citations
  5. 5Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy2019 · 52 citations